Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)



Status:Archived
Conditions:Liver Cancer, Cancer, Gastrointestinal, Digestive Disease
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:January 2010

Use our guide to learn which trials are right for you!


The primary objective of this study is to assess the overall survival (OS) of oral linifanib
given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per
standard of care in subjects with advanced or metastatic HCC.



We found this trial at
13
sites
?
mi
from
Portland, OR
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Englewood, CO
Click here to add this to my saved trials
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
LaVerne, CA
Click here to add this to my saved trials
?
mi
from
Newark, DE
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials